Piper wallichii amide alkaloid, and related products, preparation method, application and quality standard thereof
Through the combination of ethanol aqueous solution and macroporous adsorption resin, the extraction process of henanamide alkaloids is optimized, the problem of insufficient adsorption force of cation exchange resin method is solved, the extraction efficiency and analgesic effect are improved, and the stability of Preparation method and detection standards.
Patent Information
- Application Number
- CN202410927499.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-07-11
AI Technical Summary
The prior art has not provided a better method for extracting icantamide alkaloids in Henantuna, nor has it been possible to provide henantunatu alkaloid products with better analgesic effects. The cation exchange resin method is There are problems of insufficient adsorption capacity and loss of drug-effective substances during the extraction process.
The extraction process of the henanamide alkaloids is optimized by combining the aqueous ethanol solution with macroporous adsorption resin through reflux extraction, loading, elution and under-pressure concentration steps, and the total alkaloid content and active ingredients are improved. and the quality standard is set through UPLC fingerprint.
It significantly improves the extraction efficiency and analgesic effect of henan amide alkaloids, achieves more efficient use of henan Chinese medicinal materials, overcomes the problem of precipitation of fat-soluble alkaloids on the column precipitation, and provides stable preparation Methods and detection standards.
Smart Images

Figure CN118878504A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of active ingredients of traditional Chinese medicines, and relates to celastron amide alkaloids and related products, preparation methods, applications and quality standards thereof. Background Art
[0002] Pain is an unpleasant feeling with complex and diverse causes. According to the form and characteristics of pain, it can be classified from the central nervous system, inflammation and duration of the disease. Analgesia means stopping pain. A three-step treatment method can be selected for cancer pain. Non-opioid analgesics such as ibuprofen and aspirin are the first choice. When these drugs do not work, consider using weak opioid analgesics or opioid analgesics. Non-opioid analgesics are not effective for the treatment of moderate to severe cancer pain. Although opioids can have analgesic effects, they have side effects such as psychological dependence. Therefore, finding a new, safer and more effective analgesic, especially non-opioid substances, has become a bottleneck technical problem that needs to be broken through.
[0003] Heather, also known as Nanteng (Kaibao Materia Medica), Dingfu, Dinggongji (Bielu), Dinggongteng (Bencao Shiyi), Soushanhu (Diannan Materia Medica), Fengteng (Compendium of Materia Medica), Bayanxiang (Classification of Herbal Properties). It is the dried vine stem of Heather (Piper wallichii (Miq.) Hand.-Mazz.), a plant of the genus Piper in the Piperaceae family. Heather contains sea wind vine ketone, magnolia resin B, N-isobutyldecyl-trans-2-trans-4-dienamide, Nantengsu, shankonone C, Gailgraven, dihydropiperglycin, long-spiked croton epoxy and flavonoid compounds. Heather is pungent, sweet, warm, and enters the liver and kidney meridians. It can dispel rheumatism, strengthen the waist and knees, tonify the kidney and strengthen yang, relieve cough and asthma, and promote blood circulation and relieve pain. It is mainly used to treat wind-cold-dampness arthralgia, back and knee pain, impotence, cough and asthma, dysmenorrhea, and swelling and pain caused by falls. Modern medicine shows that the extract of Heather can treat coronary heart disease, angina pectoris and cerebral infarction.
[0004] Patent CN115770276A discloses a method for improving the efficacy and stability of rheumatism wine, which uses 27 medicinal materials including thorn bark, ephedra, fructus aurantii, cinnamon twig, silkworm excrement, polygonatum, tangerine peel, magnolia bark, bitter almond, oriental rhizome, yam, atractylodes, peony bark, ligusticum chuanxiong, atractylodes, angelica, costusroot, paeonia lactiflora, notopterygium, cumin, saposhnikovia divaricata, psoralea corylifolia, cyperus rotundus, dodder seed, myrrh, angelica sinensis, and frankincense as main raw materials, adopts two times of white wine percolation method, combined with polytetrafluoroethylene based membrane treated with polyoxyethylene laurate, alkyl glycoside, nano alumina and anhydrous ethanol as modifiers, effectively improving the efficacy and stability of the product; and then using egg white powder and bentonite as clarifiers, not only the clarification rate is improved, but also the product stability can be further improved.
[0005] Patent CN113599484A discloses a Chinese medicine composition for treating pain, its preparation method and application. The Chinese medicine composition provided by the technology is made of the following raw materials by weight: 515 parts by weight of Photinia serrulata, 515 parts by weight of agave root, 110 parts by weight of radix ophiopogonis, and 110 parts by weight of dried ginger. The Chinese medicine composition inhibits the occurrence of inflammation by reducing the levels of inflammatory factors and tumor necrosis factor in the serum of acetic acid analgesic model mice, thereby achieving the effect of analgesia.
[0006] Patent CN117442698A discloses the use of a Chinese medicine composition in the preparation of a medicine for exogenous evil pestilence. The Chinese medicine composition is derived from the folk traditional Chinese medicine compound Nanteng analgesic prescription, and is prepared from raw materials including Nanteng, Wa Cao root, dried ginger and Wanggua root. This technology first discovered that the Chinese medicine composition has an obvious effective therapeutic effect on diseases caused by exogenous evil pestilence or their sequelae. At the same time, the Chinese medicine composition has diverse targets, is not easy to produce drug resistance, and has no adverse reactions or fewer adverse reactions. .
[0007] At present, there are few reports on the purification of total alkaloids of spatholobi amide. The article "Screening and purification of analgesic active sites of spatholobi odoratissimus" (Journal of Chinese Patent Medicine, March 2023, Vol. 45, No. 3, pp. 1007-1011) describes the preparation method of the elution fraction of spatholobi odoratissimus cationic resin, which is aimed at separating total alkaloids, but in fact, most of the alkaloids in spatholobi odoratissimus exist in the form of amides, such as spatholobi amide and pellitorine.
[0008] The chemical structure of fennel amide is as follows:
[0009]
[0010] The chemical formula of pellitoryline is as follows:
[0011]
[0012] Amide alkaloids are almost not alkaline, and the adsorption of cation exchange resin on amide alkaloids of Heather is very easy to be eluted, which results in the presence of other substances in addition to amide alkaloids in the effective part, which affects the analgesic effect to a certain extent. Different parts separated by cation exchange resin have analgesic effects on acetic acid-induced pain in mice. On the one hand, amide alkaloids are poorly water-soluble and exist in the form of precipitation in the sample solution. The resin has incomplete adsorption, which causes the loss of effective substances; on the other hand, the medicinal parts of Heather vary from region to region. The cation exchange resin method uses dried stems and branches with leaves or the whole plant. The pharmacological verification in the early stage showed that Heather leaves do not have analgesic effects. The content of leaves in the raw materials seriously affects the analgesic effect of the drug, which also leads to the failure of this part to well tap the analgesic potential of the effective parts of Heather.
[0013] In the article "Study on HPLC Characteristic Spectrum of Heather and Determination of Amide Content" (Journal of Chinese Medicinal Materials, April 2022, Vol. 45, No. 4, pp. 922-926), a HPLC characteristic spectrum of Heather and its identification method were provided to crudely extract and identify the components in Heather. However, this method failed to achieve a more complete extraction of the components in Heather.
[0014] In summary, the prior art fails to provide a better method for extracting briar amide alkaloids from briar vine, and also fails to provide a briar amide alkaloid product with better analgesic effect. Summary of the invention
[0015] In view of this, in view of the problem that the prior art fails to provide a better method for extracting briar amide alkaloids from briar vine, the object of the present invention is to provide a briar amide alkaloid and related products, preparation methods, applications, and quality standards.
[0016] To achieve the above-mentioned purpose of the invention, on the one hand, the present invention provides a celastrin alkaloids, wherein the mass content of total alkaloids in the celastrin alkaloids is 50.05%-55.58%, the mass content of celastrin is 22.28‰-31.10‰, and the mass content of pellitorine is 9.18%-13.95%;
[0017] The UPLC fingerprint of the celastron amide alkaloids includes fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11, the position of the fingerprint peak 1 is 3.90-4.10min, the position of the fingerprint peak 6 is 12.45-12.55min, the position of the fingerprint peak 7 is 12.80-12.95min, the position of the fingerprint peak 9 is 13.10-13.25min, and the position of the fingerprint peak 11 is 15.30-15.45min.
[0018] Preferably, the chromatographic conditions of the UPLC include:
[0019] Chromatographic column: C 18 Chromatographic columns;
[0020] With water as mobile phase A and acetonitrile as mobile phase B, the gradient elution scheme is as follows:
[0021]
[0022]
[0023] The column temperature was 35°C, the flow rate was 0.8 mL / min, and the detection wavelength was 260 nm.
[0024] The percentages of mobile phase A and mobile phase B are in volume percentages. For example, when the elution time is 0-4 min, 83% of mobile phase A and 17% of mobile phase B are used.
[0025] More preferably, and as an example of the present invention, the C 18 The model of the chromatographic column is: Poroshell 120EC-C 18 1.9μm, 2.1×50mm.
[0026] Preferably, the UPLC fingerprint of the celastron amide alkaloids also includes fingerprint peak 2, fingerprint peak 3, fingerprint peak 4, fingerprint peak 5, fingerprint peak 8 and fingerprint peak 10, the position of the fingerprint peak 2 is 5.85-6.05min, the position of the fingerprint peak 3 is 8.85-8.95min, the position of the fingerprint peak 4 is 9.30-9.50min, the position of the fingerprint peak 5 is 12.15-12.30min, the position of the fingerprint peak 8 is 13.00-13.05min, and the position of the fingerprint peak 10 is 13.90-14.00min.
[0027] Preferably, the component corresponding to the fingerprint peak 1 is diatomite; the component corresponding to the fingerprint peak 6 is phenoxyethanolamide; the component corresponding to the fingerprint peak 7 is pipersintenamide; the component corresponding to the fingerprint peak 9 is pellorhinine; the component corresponding to the fingerprint peak 11 is (2E, 4E)-N-(2-methylpropyl)-dodeca-2,4-dienamide.
[0028] Wherein, the chemical structural formula of Pipersintenamide is
[0029]
[0030] Preferably, the ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.435-1.868: 1.053-1.470: 1.505-1.986: 10.950-16.640: 0.975-1.040.
[0031] More preferably, the ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.530-1.615: 1.185-1.470: 1.774-1.802: 12.012-16.640: 0.993-1.007.
[0032] Most preferably, and as an example of the present invention, the ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.600:1.470:1.780:16.640:1.001.
[0033] In another aspect, the present invention provides a method for preparing celastrin amide alkaloids, comprising the following steps:
[0034] S1, mixing the heather vine with an ethanol aqueous solution, and performing reflux extraction to obtain an extract;
[0035] S2, mixing the extract obtained in step S1 with a macroporous adsorption resin, stirring, and concentrating under reduced pressure until there is no alcohol taste, to obtain a sample mixture;
[0036] S3, loading the loading mixture obtained in step S2, letting it stand, flowing out, eluting, and obtaining an eluate;
[0037] S4, concentrating the eluate obtained in step S3 under reduced pressure, and drying to obtain celandine amide alkaloids.
[0038] Preferably, in step S1, the concentration of the ethanol aqueous solution is 70%-80%.
[0039] More preferably, and as an example of the present invention, in step S1, the concentration of the ethanol aqueous solution is 70%-80%.
[0040] Preferably, in step S1, the mass ratio of the heather spatholobi to the ethanol aqueous solution is 1:10-20.
[0041] More preferably, and as an example of the present invention, in step S1, the mass ratio of the heather spatholobi to the ethanol aqueous solution is 1:14.
[0042] Preferably, in step S1, the reflux extraction is performed 1-3 times.
[0043] More preferably, and as an example of the present invention, in step S1, the reflux extraction is performed twice.
[0044] Preferably, in step S1, the reflux extraction is performed for 1-4 hours each time.
[0045] More preferably, and as an example of the present invention, in step S1, the reflux extraction is performed for 2 hours each time.
[0046] Preferably, in step S2, the type of the macroporous resin is selected from HP-20, D101, S-8, NKA-9, DA201 and HP2MGL.
[0047] More preferably, in step S2, the type of the macroporous resin is selected from HP-20, D101, S-8 and NKA-9.
[0048] More preferably, in step S2, the type of the macroporous resin is selected from HP-20 and S-8.
[0049] More preferably, in step S2, the type of the macroporous resin is HP-20.
[0050] Preferably, the ratio of the weight of the heather vine in step S1 to the dry weight of the macroporous resin in step S2 is 1:0.4-1.2.
[0051] More preferably, the ratio of the weight of the heather vine in step S1 to the dry weight of the macroporous resin in step S2 is 1:0.6-1.
[0052] More preferably, the ratio of the weight of the heather vine in step S1 to the dry weight of the macroporous resin in step S2 is 1:0.8.
[0053] Preferably, in step S2, the stirring is for 10-30 min.
[0054] Preferably, in step S2, the reduced pressure concentration is performed at 40-60°C.
[0055] Preferably, in step S2, the macroporous adsorption resin is a pretreated macroporous adsorption resin.
[0056] More preferably, the pretreatment comprises the following steps:
[0057] Soak in ethanol for 24 hours, then soak in 5% hydrochloric acid solution for 24 hours, wash with water until neutral, then soak in 5% NaOH solution for 24 hours, wash with water until neutral, filter and dry.
[0058] Preferably, in step S3, the standing time is 15-30 minutes.
[0059] More preferably, and as an example of the present invention, in step S3, the standing time is 20 minutes.
[0060] Preferably, in step S3, the outflow rate is 2-4 BV / h.
[0061] Step S2 and step S3 of the present invention adopt a sample loading process flow of mixing the filtrate obtained by alcohol extraction with a macroporous resin, concentrating under reduced pressure to remove alcohol, loading a column, standing, and flowing out, which combines the advantages of wet sample loading and dry sample loading, and can effectively solve the problem of column blocking by fat-soluble alkaloid components in glaucoma amide alkaloids.
[0062] More preferably, and as an example of the present invention, in step S3, the outflow rate is 2BV / h.
[0063] Preferably, in step S3, the elution comprises the following steps:
[0064] S31, 3-5 BV of water is eluted at a flow rate of 2-4 BV / h to obtain a water-washed part liquid;
[0065] S32, eluting 3-5 BV with a 25%-30% ethanol aqueous solution at a flow rate of 2-4 BV / h to obtain an alcohol-washed fraction solution;
[0066] S33. Elute 9-12 BV with 40-80% ethanol aqueous solution at a flow rate of 2-4 BV / h to obtain an eluate.
[0067] More preferably, and as an example of the present invention, in step S31, 3BV is eluted with water at a flow rate of 3BV / h.
[0068] More preferably, and as an example of the present invention, in step S32, 5 BV is eluted with a 30% ethanol aqueous solution at a flow rate of 3 BV / h.
[0069] More preferably, in step S33, 9-12 BV is eluted with 70%-80% ethanol aqueous solution at a flow rate of 2-4 BV / h.
[0070] More preferably, in step S33, 9-12 BV is eluted with 70%-80% ethanol aqueous solution at a flow rate of 3 BV / h.
[0071] Further preferably, in step S33, 9-12 BV is eluted with 75% ethanol aqueous solution at a flow rate of 3 BV / h.
[0072] More preferably, and as an example of the present invention, in step S33, 10 BV is eluted with a 75% ethanol aqueous solution at a flow rate of 3 BV / h.
[0073] Preferably, in step S4, the reduced pressure concentration is performed at 40-60° C., and the drying is freeze-drying.
[0074] On the other hand, the present invention provides the water-washed fraction of glaucoma alkaloids obtained by the above-mentioned preparation method, and the preparation method comprises the following steps: drying the water-washed fraction liquid obtained in step S31 of the above-mentioned preparation method to obtain the water-washed fraction of glaucoma alkaloids.
[0075] On the other hand, the present invention provides the alcohol-washed fraction of celastron alkaloids obtained by the above-mentioned preparation method, and the preparation method comprises the following steps: drying the alcohol-washed fraction liquid obtained in step S32 of the above-mentioned preparation method to obtain the alcohol-washed fraction of celastron alkaloids.
[0076] On the other hand, the present invention provides the use of the above-mentioned celandine amide alkaloids and / or the celandine amide alkaloids obtained by the above-mentioned preparation method and / or the water-washed fraction of the above-mentioned celandine amide alkaloids and / or the alcohol-washed fraction of the above-mentioned celandine amide alkaloids in the preparation of analgesic products.
[0077] Preferably, the analgesia is for traumatic pain, thermal pain, inflammatory pain and bone cancer pain.
[0078] More preferably, the analgesic product is an analgesic drug.
[0079] On the other hand, the present invention provides an analgesic drug, the active ingredients of which include the above-mentioned briar amide alkaloids and / or the briar amide alkaloids obtained by the above-mentioned preparation method and / or the water-washed fraction of the above-mentioned briar amide alkaloids and / or the alcohol-washed fraction of the above-mentioned briar amide alkaloids.
[0080] The drug can be prepared into dosage forms such as pills, capsules, granules, oral liquids, powders, tablets, lozenges and injections, and suitable drug carriers in the art can be selected for different dosage forms.
[0081] The pharmaceutical carrier used can be solid, liquid or gas. Examples of solid carriers include lactose, kaolin, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate and stearic acid. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen.
[0082] When preparing drugs in oral dosage forms, any convenient pharmaceutical medium can be used. For example, water, ethanol, oil, alcohol, flavoring agents, preservatives, colorants, etc. can be used to form oral liquid preparations, such as suspensions, elixirs and solutions; while carriers, such as starch, sugars, microcrystalline cellulose, diluents, granulating agents, emulsifiers, lubricants, binders, disintegrants can be used to form oral solid preparations, such as powders, capsules and tablets. Tablets and capsules are preferred oral dosage units using solid pharmaceutical carriers due to their ease of administration. Tablets can be coated using standard aqueous or non-aqueous techniques.
[0083] Tablets containing the glaucoma amide alkaloids prepared by the present invention can be prepared by tableting or molding, and one or more auxiliary ingredients or adjuvants can be used. The active ingredient can be tableted in a free-flowing form (such as powder or granules) in a suitable machine, and can be optionally mixed with a binder, a lubricant, an inert diluent, a surfactant or a dispersant to prepare the tablet. Molded tablets can be molded in a suitable machine, that is, a powdered compound mixture moistened with an inert liquid diluent. Each tablet preferably contains about 0.05 mg to about 5 g of active ingredient, and each sachet or capsule preferably contains about 0.05 mg to about 5 g of active ingredient. For example, a preparation intended for oral administration to humans may contain about 0.5 mg to about 5 g of active drug, mixed with an appropriate and convenient carrier material, which may account for about 5% to 95% of the total composition. Dosage unit forms will generally contain from about 1 mg to about 2 g of active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
[0084] The medicine suitable for parenteral administration in the present invention can be prepared as an aqueous solution or suspension. Suitable surfactants, such as hydroxypropylcellulose, can be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycol and oil mixtures thereof. In addition, preservatives can be added to prevent the harmful growth of microorganisms.
[0085] The drugs suitable for injection use in the present invention include sterile aqueous solutions or dispersions. In addition, the drug can be in the form of sterile powders for the extemporaneous preparation of such sterile injections or dispersions. In all cases, the final injection form must be sterile and must be an effective liquid so that the injectable drug component must remain stable under production and storage conditions; therefore, it is best to preserve it to prevent the contamination of microorganisms (such as bacteria and fungi). The carrier can be a solvent or dispersion medium, for example, containing water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils and suitable mixtures thereof.
[0086] The medicine of the present invention can be in a form suitable for topical use, such as an aerosol, cream, ointment, lotion, powder or the like. In addition, the medicine can be in a suitable form for transdermal administration devices. These prescriptions can be prepared using the medicine of the present invention by conventional processing methods. For example, a cream or ointment with a desired consistency can be prepared by mixing a hydrophilic material and water, and about 5wt% to about 10wt% of the compound.
[0087] The medicine of the present invention can be in a form suitable for rectal administration, wherein the carrier is a solid. Preferably, the mixture is made into a unit dose suppository. Suitable carriers include cocoa butter and other materials commonly used in the art. Suppositories can be prepared by first forming a composition containing a softened or melted carrier, followed by cooling and shaping in a mold.
[0088] In addition to the above-mentioned carrier components, the above-mentioned drugs may include (if applicable) one or more additional carrier components, such as diluents, buffers, flavoring agents, adhesives, surfactants, thickeners, lubricants, preservatives (including antioxidants), etc. In addition, other excipients, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc., colorants and flavoring agents, etc., may be added. The preparation is made isotonic with the blood of the intended recipient. The components containing the sedum amide alkaloids of the present invention can also be prepared in the form of powder or concentrate.
[0089] Preferably, the dosage form of the drug is selected from pills, capsules, granules, oral liquids, powders, tablets, lozenges and injections.
[0090] Preferably, the drug is an oral drug.
[0091] In another aspect, the present invention provides the quality standard of the above-mentioned celastrin alkaloids, including total alkaloid content detection, celastrin content detection, pellitorine content detection and UPLC fingerprint detection of celastrin alkaloids;
[0092] The UPLC fingerprint detection method of the celastrin alkaloids comprises the following steps:
[0093] The sedum amide alkaloids were dissolved in 75% methanol, sonicated to remove solids, injected into a liquid chromatograph for UPLC detection, and a UPLC fingerprint was obtained;
[0094] The quality of celastrin amide alkaloids was evaluated based on the obtained UPLC fingerprints, and the evaluation criteria included:
[0095] (1) The UPLC fingerprint spectrum includes fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11, the position of the fingerprint peak 1 is 3.90-4.10 min, the position of the fingerprint peak 6 is 12.45-12.55 min, the position of the fingerprint peak 7 is 12.80-12.95 min, the position of the fingerprint peak 9 is 13.10-13.25 min, and the position of the fingerprint peak 11 is 15.30-15.45 min;
[0096] (2) The UPLC fingerprint spectrum also includes fingerprint peak 2, fingerprint peak 3, fingerprint peak 4, fingerprint peak 5, fingerprint peak 8 and fingerprint peak 10. The position of the fingerprint peak 2 is 5.85-6.05 min, the position of the fingerprint peak 3 is 8.85-8.95 min, the position of the fingerprint peak 4 is 9.30-9.50 min, the position of the fingerprint peak 5 is 12.15-12.30 min, the position of the fingerprint peak 8 is 13.00-13.05 min, and the position of the fingerprint peak 10 is 13.90-14.00 min.
[0097] Preferably, the standard for detecting the total alkaloid content is: total alkaloid mass content ≥ 50.05%.
[0098] More preferably, the standard for detecting the total alkaloid content is: the total alkaloid mass content is 50.05%-55.58%.
[0099] Preferably, the method for detecting the total alkaloid content comprises the following steps:
[0100] Preparation of chromotropic acid concentrated sulfuric acid solution; preparation of reference solution; acquisition of standard curve; preparation of freeze-dried powder sample solution; UV-visible spectrum detection.
[0101] More preferably, the method for detecting the total alkaloid content comprises the following steps:
[0102] Preparation of chromotropic acid concentrated sulfuric acid solution: add 0.2g chromotropic acid powder to 200mL 90% concentrated sulfuric acid solution, stir to dissolve, and obtain chromotropic acid concentrated sulfuric acid solution;
[0103] Obtaining the standard curve: accurately pipette 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 mL of the reference solution into a 10 mL stoppered glass test tube, accurately add 5 mL of chromotropic acid concentrated sulfuric acid solution, suspend evenly, heat in a boiling water bath for 30 min, dilute to 10 mL with water, measure the absorbance at 485 nm, and draw a standard curve with concentration as the horizontal axis and absorbance as the vertical axis;
[0104] Preparation of freeze-dried powder sample solution: take 10 mg of freeze-dried powder, weigh accurately, put it in a stoppered conical bottle, stopper and weigh it, add 25 mL of 75% methanol and sonicate for 30 minutes, take it out and cool it to room temperature, make up the lost weight with 75% methanol, shake well and filter, take the filtrate, which is the freeze-dried powder sample solution;
[0105] UV-visible spectrum detection: Accurately pipette 0.2 mL of the freeze-dried powder sample solution into a 10 mL stoppered glass test tube, accurately add 5 mL of chromotropic acid concentrated sulfuric acid solution, suspend evenly and heat in a boiling water bath for 30 min, dilute to 10 mL with water to obtain the test solution, determine the absorbance, and use the obtained standard curve to determine the total amide alkaloid content in the freeze-dried powder.
[0106] Preferably, the standard for detecting the content of fennel amide is: the mass content of fennel amide is ≥ 22.28‰.
[0107] More preferably, the standard for detecting the content of fennel amide is: the mass content of fennel amide is 22.28‰-31.10‰.
[0108] Preferably, the standard for detecting the content of pellitoryline is: the mass content of pellitoryline is ≥ 9.18%.
[0109] More preferably, the standard for detecting the pellitoryline content is: the pellitoryline mass content is 9.18%-13.95%.
[0110] Preferably, the method for detecting the fennel amide content and the pellitoryrine content is liquid chromatography detection.
[0111] More preferably, the method for detecting the content of fennel amide and the content of pellitoryline comprises the following steps:
[0112] Take an appropriate amount of reference substance, weigh accurately, and add an appropriate amount of methanol to prepare a 20 μg / mL reference substance solution;
[0113] Take about 10 mg of freeze-dried powder, weigh it accurately, put it in a stoppered conical bottle, stopper it and weigh it, add 25 mL of 75% methanol and sonicate for 0 min, take it out and let it cool to room temperature, make up the lost weight with 75% methanol, shake it well and filter it, take the filtrate, dilute it 1 time with methanol, centrifuge it at 10000 r / min for 5 min, and pass it through a 0.22 μm microporous filter to get the test solution;
[0114] Accurately pipette 5 μL of reference solution and test solution respectively, inject into liquid chromatograph for liquid chromatography analysis to obtain.
[0115] The above-mentioned standards for detecting total alkaloid content, standards for detecting fusinamide content and standards for detecting pellitoryline content are all standards for the qualified quality of fusinamide alkaloids.
[0116] Preferably, the step of removing solids comprises filtering to obtain a filtrate and centrifuging to obtain a supernatant.
[0117] Preferably, the chromatographic conditions of the UPLC detection include:
[0118] Chromatographic column: C 18Chromatographic columns;
[0119] With water as mobile phase A and acetonitrile as mobile phase B, the gradient elution scheme is as follows:
[0120] Elution time / min Mobile phase A / % Mobile phase B / % 0-4 83 17 4-8.7 83-75 17-25 8.7-10.6 75-68 25-32 10.6-12 68-50 32-50 12-17 50 50 17-20 50-10 50-90
[0121] The column temperature was 35°C, the flow rate was 0.8 mL / min, and the detection wavelength was 260 nm.
[0122] More preferably, the C 18 The model of the chromatographic column is: Poroshell 120EC-C 18 1.9μm, 2.1×50mm.
[0123] Preferably, the ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.435-1.868: 1.053-1.470: 1.505-1.986: 10.950-16.640: 0.975-1.040.
[0124] More preferably, the ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.530-1.615: 1.185-1.470: 1.774-1.802: 12.012-16.640: 0.993-1.007.
[0125] Compared with the prior art, the present invention has the following beneficial effects:
[0126] (1) A method for preparing glaucoma amide alkaloids is provided. By optimizing the preparation process such as the resin model for purification, the ratio of the amount of crude drug to the dry mass of the resin, and the elution conditions, the total alkaloid content, the content of the effective ingredients glaucoma and pellitoryline, the transfer rate, and the powder yield of the product in the glaucoma amide alkaloid product are greatly improved, thereby achieving a more efficient use of glaucoma traditional Chinese medicine to extract glaucoma alkaloids.
[0127] (2) The present invention optimizes the loading method of the macroporous resin for heather amide alkaloids, effectively overcoming the problem that the fat-soluble amide alkaloids are easily blocked by the column, and provides a method for the purification of similar fat-soluble substances by macroporous resin.
[0128] (3) The method for preparing celastrin alkaloids provided by the present invention is stable and easy to repeat. The inter-group standard deviations of parameters such as the total content of alkaloids, the content of active ingredients celastrin and celastrin, the transfer rate and the powder yield of the product are small, which is conducive to promotion and application.
[0129] (4) The celastrin amide alkaloids prepared by the preparation method provided by the present invention can achieve better analgesic function and can effectively relieve bone cancer pain in experimental mice.
[0130] (5) The present invention also provides a detection standard for celastron amide alkaloids, which fills the gap in the current detection standard for celastron amide alkaloid products. BRIEF DESCRIPTION OF THE DRAWINGS
[0131] Figure 1 This is the UPLC fingerprint of the celastron amide alkaloids in Example 1 and the control fingerprint of its fingerprint peaks 1, 6, 7, 9, and 11.
[0132] Figure 2 It is a bar graph of the Western Blot results of the effect of celastron amide alkaloids on the expression level of TPRV1 in the dorsal root ganglion of mice in the efficacy example 1;
[0133] Wherein, group N represents a blank group, M represents a model group, Y represents a positive control group, S-1 represents the water extraction fraction of the strychnine amide alkaloids prepared in Example 1, S-2 represents the alcohol extraction fraction of the strychnine amide alkaloids prepared in Example 1, and S-3 represents the strychnine amide alkaloids prepared in Example 1;
[0134] In A, ### indicates that P < 0.05 between group N and group M, ns indicates that there is no significant difference between group M and group Y; *** indicates that P < 0.001 between groups S-1, S-2, S-3 and groups N, M, Y;
[0135] In B, *** indicates P < 0.001 between groups S-1, S-2 and group S-3. DETAILED DESCRIPTION
[0136] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.
[0137] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.
[0138] Example 1
[0139] The preparation of celastrin amide alkaloids is as follows:
[0140] S1. Take Heather strychnifolia, crush it and then extract it with 14 times the mass of 75% ethanol aqueous solution by reflux, repeat twice, extract for 2 hours, and combine the extracts.
[0141] S2. Pre-treat the HP-20 macroporous adsorption resin: soak it in ethanol for 24 hours, then soak it in 5% hydrochloric acid solution for 24 hours, wash it with water until it is neutral, then soak it in 5% NaOH solution for 24 hours, wash it with water until it is neutral, filter it, and dry it.
[0142] Take an appropriate volume of the pretreated HP-20 macroporous adsorption resin and stir and mix it with the extract obtained in step S1. The ratio of the mass of Heather vine to the dry mass of the macroporous adsorption resin in step S1 is 1:0.8. Stir for 20 minutes, mix thoroughly and evenly, and concentrate under reduced pressure at 40-60°C until there is no alcohol smell to obtain a sample mixture.
[0143] S3, the sample mixture obtained in step S2 is loaded onto the column. Let it stand for 20 minutes, and then flow out at a flow rate of 2BV / h. Then, elute
[0144] S31, washing 3BV with water at a flow rate of 3BV / h to obtain a water-washed part liquid;
[0145] S32, eluting 5 BV with 30% ethanol aqueous solution at 3 BV / h to obtain an alcohol wash fraction solution;
[0146] S33. Elute 10 BV with 75% ethanol aqueous solution at a flow rate of 3 BV / h to obtain an eluate.
[0147] S4, the eluate obtained in step S3 is concentrated under reduced pressure at 40-60°C until the ratio of the mass of spatholobi to the volume of the liquid in step S1 is 0.1 g:1 mL, and freeze-dried to obtain spatholobi amide alkaloids (lyophilized powder).
[0148] The water-washed fraction obtained in step S31 is decompressed, concentrated, and dried to obtain the celastron amide alkaloid water-washed fraction.
[0149] The alcohol-washed fraction obtained in step S32 is decompressed, concentrated, and dried to obtain the alcohol-washed fraction of the celastron amide alkaloids.
[0150] The obtained celastrin amide alkaloids were characterized by UPLC fingerprint. The characterization process is as follows:
[0151] Take about 10 mg of spatholobiaceae alkaloids, weigh accurately, put them in a stoppered conical flask, weigh the weight, add 25 mL of 75% methanol and ultrasonicate (40 kHz, 100 W) for 30 minutes, take out and cool to room temperature, make up the lost weight with 75% methanol, shake well and filter, take the filtrate, dilute it 1 times with methanol, centrifuge at 10000r / min for 5 minutes, pass through a 0.22μm microporous filter head, and obtain the test solution for single component content determination. Accurately aspirate 5μL of the reference solution and the test solution respectively, and inject them into the liquid chromatograph for UPLC detection. The chromatographic conditions of the UPLC are:
[0152] Column: Poroshell 120EC-C 18 1.9μm, 2.1×50mm column;
[0153] With water as mobile phase A and acetonitrile as mobile phase B, the gradient elution scheme is as follows:
[0154] Elution time / min Mobile phase A / % Mobile phase B / % 0-4 83 17 4-8.7 83-75 17-25 8.7-10.6 75-68 25-32 10.6-12 68-50 32-50 12-17 50 50 17-20 50-10 50-90
[0155] The column temperature was 35°C, the flow rate was 0.8 mL / min, and the detection wavelength was 260 nm.
[0156] The characterization results are as follows Figure 1 shown.
[0157] The UPLC fingerprint of celastrin alkaloids includes fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11. The position of fingerprint peak 1 is 3.90-4.10min, the position of fingerprint peak 6 is 12.45-12.55min, the position of fingerprint peak 7 is 12.80-12.95min, the position of fingerprint peak 9 is 13.10-13.25min, and the position of fingerprint peak 11 is 15.30-15.45min.
[0158] The peak area ratios of fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11 are:
[0159] 1.600:1.470:1.780:16.64:1.001.
[0160] Among them, fingerprint peak 1 represents purple jade plate diamide; fingerprint peak 6 represents wind vine amide; fingerprint peak 7 represents pipersintenamide; fingerprint peak 9 represents wallwort alkaloid; fingerprint peak 11 represents (2E, 4E)-N-(2-methylpropyl)-dodeca-2,4-dienamide.
[0161] The UPLC fingerprint spectrum also includes fingerprint peak 2, fingerprint peak 3, fingerprint peak 4, fingerprint peak 5, fingerprint peak 8 and fingerprint peak 10. The position of fingerprint peak 2 is 5.85-6.05 min, the position of fingerprint peak 3 is 8.85-8.95 min, the position of fingerprint peak 4 is 9.30-9.50 min, the position of fingerprint peak 5 is 12.15-12.30 min, the position of fingerprint peak 8 is 13.00-13.05 min, and the position of fingerprint peak 10 is 13.90-14.00 min.
[0162] Example 2
[0163] Compared with Example 1, in step S1, 10 times the mass of 75% ethanol aqueous solution is used for reflux extraction, which is repeated twice, and the rest is the same.
[0164] Example 3
[0165] Compared with Example 1, in step S1, 20 times the mass of 75% ethanol aqueous solution is used for reflux extraction, which is repeated twice, and the rest is the same.
[0166] Comparative Example 1
[0167] Compared with Example 1, in step S1, 30 times the mass of 75% ethanol aqueous solution is used for reflux extraction, which is repeated twice, and the rest is the same.
[0168] Example 4
[0169] Compared with Example 1, in step S2, D101 macroporous adsorption resin is used instead, and the rest is the same.
[0170] Example 5
[0171] Compared with Example 1, in step S2, S-8 macroporous adsorption resin is used instead, and the rest is the same.
[0172] Example 6
[0173] Compared with Example 1, in step S2, NKA-9 macroporous adsorption resin is used instead, and the rest is the same.
[0174] Example 7
[0175] Compared with Example 1, in step S2, DA201 macroporous adsorption resin is used instead, and the rest is the same.
[0176] Example 8
[0177] Compared with Example 1, in step S2, HP2MGL macroporous adsorption resin is used instead, and the rest is the same.
[0178] Comparative Example 2
[0179] Compared with Example 1, in step S2, D001 macroporous strong acid styrene-based cationic resin is used instead, and the rest is the same.
[0180] Example 9
[0181] Compared with Example 1, the dry mass ratio of the mass of Heather strychnifolia in step S1 to the dry mass of the macroporous adsorption resin in step S2 is 1:0.6, and the rest are the same.
[0182] Example 10
[0183] Compared with Example 1, the dry mass ratio of the mass of Heather strychnifolia in step S1 to the dry mass of the macroporous adsorption resin in step S2 is 1:1, and the rest are the same.
[0184] Embodiment 11
[0185] Compared with Example 1, the dry mass ratio of the mass of Heather strychnifolia in step S1 to the dry mass of the macroporous adsorption resin in step S2 is 1:0.4, and the rest are the same.
[0186] Example 12
[0187] Compared with Example 1, the dry mass ratio of the mass of Heather strychnifolia in step S1 to the dry mass of the macroporous adsorption resin in step S2 is 1:1.2, and the rest are the same.
[0188] Comparative Example 3
[0189] Compared with Example 1, the dry mass ratio of the mass of Heather strychnifolia in step S1 to the dry mass of the macroporous adsorption resin in step S2 is 1:0.35, and the rest are the same.
[0190] Embodiment 13
[0191] Compared with Example 1, in step S3, the step of standing for 15 minutes is changed, and the rest is the same.
[0192] Embodiment 14
[0193] Compared with Example 1, in step S3, the step of standing for 30 minutes is changed, and the rest is the same.
[0194] Comparative Example 4
[0195] Compared with Example 1, in step S3, the step of standing for 24 hours is changed, and the rest is the same.
[0196] Embodiment 15
[0197] Compared with Example 1, in step S32, 5 BV is eluted with 25% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0198] Comparative Example 5
[0199] Compared with Example 1, in step S32, 5 BV is eluted with 65% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0200] Example 16
[0201] Compared with Example 1, in step S33, 10 BV is eluted with 70% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0202] Embodiment 17
[0203] Compared with Example 1, in step S33, 10 BV is eluted with 80% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0204] Comparative Example 6
[0205] Compared with Example 1, in step S33, 10 BV is eluted with 95% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0206] Comparative Example 7
[0207] Compared with Example 1, in step S33, 10 BV is eluted with 50% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0208] Embodiment 18
[0209] Compared with Example 1, in step S33, 9 BV is eluted with 75% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0210] Embodiment 19
[0211] Compared with Example 1, in step S33, 12 BV is eluted with 75% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0212] Comparative Example 8
[0213] Compared with Example 1, in step S33, 8 BV is eluted with 75% ethanol aqueous solution at 3 BV / h, and the rest is the same.
[0214] Comparative Example 9
[0215] Compared with Example 1, in step S3, the step of standing for 20 minutes is omitted, and the rest is the same.
[0216] Comparative Example 10
[0217] Refer to the method for extracting the effective components of Heather vine recorded in the article "Screening and purification of analgesic active parts of Heather vine" (Journal of Chinese Patent Medicine, March 2023, Vol. 45, No. 3, pp. 1007-1011) to extract Heather vine. The specific steps are as follows:
[0218] Take an appropriate amount of Heather strychnifolia, crush it and extract it twice with 14 times the mass of 75% ethanol aqueous solution by reflux, each time for 2 hours. Combine the extracts, concentrate under reduced pressure until there is no alcohol taste, and obtain the total extract. Suspend the total extract with an appropriate amount of water and wet-load it on a D001 macroporous cationic adsorption resin column. Take 2BV 0.4g / mL of the sample solution, flow it through the resin, and elute it with 5BV 70% ethanol. The elution volume flow rate is 2BV / h. Collect the eluate, concentrate it under reduced pressure until there is no alcohol taste, and freeze-dry it to obtain it.
[0219] Comparative Example 11
[0220] Compared with Example 1, step S2 is replaced by the following steps:
[0221] The HP-20 macroporous adsorption resin was pretreated by soaking it in ethanol for 24 hours, then soaking it in 5% hydrochloric acid solution for 24 hours, washing it with water until it was neutral, and then soaking it in 5% NaOH solution for 24 hours, washing it with water until it was neutral, filtering it, and drying it.
[0222] Take an appropriate volume of pre-treated HP-20 macroporous adsorption resin and load it into the column. Concentrate the extract obtained in step S1 under reduced pressure at 40-60° C. until there is no alcohol smell, which is the loading mixture.
[0223] In step S3, the resin column after loading is discharged, and the loading composition is loaded. The remaining steps are the same as those in Example 1.
[0224] Comparative Example 12
[0225] Compared with Example 1, in step S4, the temperature of reduced pressure concentration is changed to 65-75° C., and the rest are the same.
[0226] In Examples 1-19 and Comparative Examples 1-12, the peak area ratios of fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11 are shown in the following table (the position of the fingerprint peak 1 is 3.90-4.10 min, the position of the fingerprint peak 6 is 12.45-12.55 min, the position of the fingerprint peak 7 is 12.80-12.95 min, the position of the fingerprint peak 9 is 13.10-13.25 min, and the position of the fingerprint peak 11 is 15.30-15.45 min):
[0227]
[0228]
[0229] Effect evaluation
[0230] 1. Yield of spatholobiamide alkaloids (lyophilized powder) prepared in Example 1-19 and Comparative Example 1-12
[0231] 1.1 Calculation method
[0232] Powder yield = freeze-dried powder weight ÷ amount of heather used × 1000‰.
[0233] 1.2 Experimental Results
[0234] The experiments of each embodiment and each comparative example were repeated 5 times, and the average value and standard deviation of the powder yield obtained each time were calculated. The results are summarized in the following table:
[0235]
[0236]
[0237] 2. Total alkaloid content in the celastron amide alkaloids (lyophilized powder) obtained in Examples 1-19 and Comparative Examples 1-12
[0238] 2.1 Determination method
[0239] Preparation of chromotropic acid concentrated sulfuric acid solution: Take an appropriate amount of pure water and add concentrated sulfuric acid to prepare a 90% concentrated sulfuric acid solution. Add 0.2g of chromotropic acid powder to 200mL of 90% concentrated sulfuric acid solution, stir to dissolve, cool and seal in a brown bottle to obtain a chromotropic acid concentrated sulfuric acid solution.
[0240] Preparation of reference solution: Take an appropriate amount of pellitoryline reference solution and add anhydrous ethanol to prepare a reference solution with a concentration of 0.2 mg / mL.
[0241] Obtaining the standard curve: accurately draw 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7mL of the reference solution, place it in a 10mL stoppered glass test tube, accurately add 5mL of chromotropic acid concentrated sulfuric acid solution, suspend evenly, heat in a boiling water bath for 30min, take it out and let it cool, then slowly add water to the scale, suspend evenly, and let it cool. Measure the absorbance at 485nm, draw a standard curve with concentration as the horizontal axis (X) and absorbance as the vertical axis (Y), and pellitorine shows a good linear relationship with the absorbance in the range of 20-140μg / mL, and the regression equation is Y=0.0016X+0.1267(R2=0.9966).
[0242] Preparation of freeze-dried powder sample solution: Take 10 mg of freeze-dried powder, weigh it accurately, put it in a stoppered conical flask, seal it and weigh it, add 25 mL of 75% methanol and ultrasonically (40 kHz, 100 W) for 30 min, take it out and let it cool to room temperature, make up the lost weight with 75% methanol, shake it well and filter it, and take the filtrate, which is the freeze-dried powder sample solution.
[0243] UV-visible spectrum detection: Accurately pipette 0.2 mL of freeze-dried powder sample solution into a 10 mL stoppered glass test tube, accurately add 5 mL of chromotropic acid concentrated sulfuric acid solution, suspend evenly, heat in a boiling water bath for 30 min, take out and cool, then slowly add water to the scale, suspend evenly, cool, and obtain the test solution. Determine the absorbance, and use the standard curve method to determine the total amide alkaloid content in the freeze-dried powder.
[0244] 2.2 Measurement results
[0245] The experiments of each embodiment and each comparative example were repeated 5 times, and the average value and standard deviation of the total alkaloid content in the lyophilized powder obtained each time were calculated. The results are summarized in the following table:
[0246]
[0247]
[0248] 3. Contents and transfer rates of fusantamide and pellitorine in the fusantamide alkaloids (lyophilized powder) obtained in Examples 1-19 and Comparative Examples 1-12
[0249] 3.1 Determination method
[0250] Chromatographic conditions:
[0251] Chromatographic column: Poroshell 120EC-C18 (1.9 μm, 2.1 × 50 mm);
[0252] With water as mobile phase A and acetonitrile as mobile phase B, the gradient elution scheme is shown in the following table:
[0253] Elution time / min Mobile phase A / % Mobile phase B / % 0-4 83 17 4-8.7 83-75 17-25 8.7-10.6 75-68 25-32 10.6-12 68-50 32-50 12-17 50 50 17-20 50-10 50-90
[0254] The column temperature was 35°C, the flow rate was 0.8 mL / min, and the detection wavelength was 260 nm.
[0255] Preparation of reference solution: Take appropriate amount of pellitoryline and fennel reference substances, weigh accurately, and add appropriate amount of methanol to prepare a 20 μg / mL reference solution.
[0256] Preparation of test solution:
[0257] Alcohol extract sample: dilute 5 times with methanol, centrifuge at 10000r / min for 5 minutes, and pass through a 0.22μm microporous filter.
[0258] Eluate and eluate samples were diluted 1-fold with methanol, centrifuged at 10,000 r / min for 5 min, and filtered through a 0.22 μm microporous filter.
[0259] Lyophilized powder sample: Take about 10 mg of lyophilized powder, weigh it accurately, put it in a stoppered conical flask, seal it and weigh it, add 25 mL of 75% methanol and ultrasonically (40 kHz, 100 W) for 30 min, take it out and let it cool to room temperature, make up the lost weight with 75% methanol, shake it well and filter it, take the filtrate, dilute it 1 times with methanol, centrifuge it at 10000 r / min for 5 min, and pass it through a 0.22 μm microporous filter to obtain the test solution for the determination of the content of a single component.
[0260] Determination operation: Accurately pipette 5 μL of reference solution and test solution respectively, inject into liquid chromatograph, and determine the result.
[0261] Transfer rate = content of single component in freeze-dried powder / content of single component in filtrate obtained in step S1 × 1000‰. Wherein, the single component is fennel amide or pellitoryline. The content of single component is detected by chromatography.
[0262] 3.2 Measurement results
[0263] The experiments for preparing celandine amide alkaloids in each embodiment and comparative example were repeated 5 times, and the average value and standard deviation of the content of celandine amide in the obtained celandine amide alkaloids were calculated. The experimental results are shown in the following table:
[0264]
[0265]
[0266] The experiments for preparing celandine amide alkaloids in each embodiment and comparative example were repeated 5 times, and the average value and standard deviation of the content of pellitorine in the celandine amide alkaloids obtained were calculated. The experimental results are shown in the following table:
[0267]
[0268]
[0269] The experiments for preparing celandine amide alkaloids in each embodiment and comparative example were repeated 5 times, and the transfer rates of celandine amide in the obtained celandine amide alkaloids were averaged and the standard deviation was calculated. The experimental results are shown in the following table:
[0270]
[0271]
[0272] The experiments for preparing celandine amide alkaloids in each embodiment and comparative example were repeated 5 times, and the transfer rates of pellitorine in the celandine amide alkaloids obtained were averaged and the standard deviations were calculated. The experimental results are shown in the following table:
[0273]
[0274]
[0275] In summary, the preparation method provided in Example 1-19 can achieve higher content and transfer rate of fennel amide and pellitoryline compared with that in Comparative Example 1-12.
[0276] Efficacy Example 1: Inhibitory Effects of Glechoma amide Alkaloids on Acute Pain and Inflammatory Pain in Mice 1. Experimental Materials
[0277] 1.1 Drugs and reagents
[0278] Heather thunbergii, positive drug ibuprofen tablets (Batch No. 2212627, Shandong Xinhua Pharmaceutical Co., Ltd.), RunningBuffer and Transfer Buffer homemade in the laboratory, 10% gel making kit (Novozymes; cat: E303; Lot: 071E2221LA), TBS (Biosharp; cat: BL602A), Tween-20 (Solabo: cat: T8220; Lot: 424E013), BSA (Biosharp: cat: BS114; Lot: 22215659), protein marker (Thermo Fisher: cat: 26616; Lot: 91295071), primary antibody TRPV1 (Bioworld: cat: BS 60454; Lot: CN89330), primary antibody β-actin (Abclonal: cat: AC004; Lot: 3500100011).
[0279] 1.2 Instruments
[0280] Electrophoresis apparatus (Bio Rad, PowerPac Basic), semi-dry transfer (Bio Rad, TRANS-BLOT SD), imager (Tianneng, 500S), centrifuge (Eppendorf, Centrifuge 5417R), IL-1β kit (lot number E0408231494R) and PGE2 kit (lot number E0408231494R) were purchased from Nanjing Sanes Biotechnology Co., Ltd., KH-30E ultrasonic cleaner (Kunshan Hechuang Ultrasonic Instrument Co., Ltd.), YWLG-10A vacuum freeze dryer (Nanjing Yanwo Biotechnology Co., Ltd.), RT-6100 microplate reader (Shenzhen Raydu Life Sciences Co., Ltd.), and TGL16M refrigerated centrifuge (Shanghai Lu Xiangyi Centrifuge Instrument Co., Ltd.).
[0281] 1.3 Animals
[0282] SPF grade ICR mice, half male and half female, with a body weight of (20±2) g, were purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd.
[0283] 2. Methods and Results
[0284] 2.1 Grouping
[0285] Random grouping (n=8). The specific grouping method is as follows:
[0286] Blank group: No pain model was established, and the mice were intragastrically administered with 0.5% sodium carboxymethyl cellulose in physiological saline solution.
[0287] Model group: pain model was established by intragastric administration of 0.5% sodium carboxymethyl cellulose in physiological saline solution.
[0288] Positive drug group: pain model was established and ibuprofen solution was gavaged (30 mg ibuprofen per kg mouse body weight per day).
[0289] Example 1 Water-washed part group: A pain model was established, and the water-washed part of the celastron amide alkaloids obtained in Example 1 was administered intragastrically.
[0290] Example 1 Alcohol-washed site group: A pain model was established, and the alcohol-washed site of the celastrin amide alkaloids obtained in Example 1 was administered intragastrically.
[0291] In each example and comparative example group, a pain model was established, and the celastron amide alkaloids obtained in each example and comparative example were intragastrically administered.
[0292] The water-washed part of the glaucoma alkaloids administered to the water-washed part group in Example 1, the alcohol-washed part of the glaucoma alkaloids administered to the alcohol-washed part group in Example 1, and the glaucoma alkaloids administered to the comparative example groups in each example were all given an oral dose of 30 mg per kilogram of mouse body weight per day.
[0293] The basic solutions used for oral administration of the above-mentioned drug-administered groups were all physiological saline solutions containing 0.5% by mass of sodium carboxymethyl cellulose.
[0294] 2.2 Experimental methods
[0295] Drug administration, modeling and sampling: The mice were adaptively raised for 7 days, and each group was gavaged for 7 consecutive days after adaptive feeding. Three days in advance of modeling, a fixed time was selected, and the mice were grasped according to the grasping method during the plantar injection to adapt to the posture of drug injection. After the adaptation, 30 minutes after the last administration, 1 μL / g of 5% formalin solution (prepared with 0.9% saline solution) was injected into the plantar of the left foot of the mice. There were 8 mice in each group. After the injection, the mice were placed in an observation cage to observe the number and time of licking the feet within 5 minutes of the acute pain period and the 10-60 minutes of the inflammatory pain period. After the observation, blood was collected from the eye sockets of the mice in each group, and the mice were killed by spinal despondency, and the dorsal root ganglia in the L4-6 joints of the mouse spine were obtained.
[0296] Data processing: Graphpad Prism 9.0 software was used for data processing. One-way analysis of variance was used for comparison among multiple groups, and P < 0.05 indicated that the difference was statistically significant.
[0297] 2.3 Experimental Results
[0298] 2.3.1 Number and duration of paw licking by mice
[0299] The results of the pain-related foot-licking time and foot-licking frequency are summarized in the following table ( n=8):
[0300]
[0301]
[0302] (Note: Compared with the model group, *P<0.05, ***P<0.001.)
[0303] As can be seen from the above table, compared with the model group, each embodiment group has a significant analgesic effect, and can significantly reduce the licking time (P<0.05) and the number of licking (P<0.001) of the painful mice; the water-washed site group of Example 1 reduced the number of licking, but the licking time was still close to the model; the alcohol-washed site group of Example 1, the positive drug ibuprofen group and the comparative groups had no significant analgesic effect on the pain.
[0304] The results of the pain licking time and number of licking in phase II are summarized in the following table ( n=8):
[0305]
[0306]
[0307] (Note: Compared with the model group, *P<0.05, **P<0.01, ***P<0.001.)
[0308] As can be seen from the above table, compared with the model group, each embodiment group has a significant analgesic effect, and can significantly reduce the licking time (P<0.01) and the number of licking times (P<0.01) of the painful mice; the positive drug group also has a significant analgesic effect, and can significantly reduce the licking time (P<0.01) and the number of licking times (P<0.001) of the painful mice; the other groups did not exert analgesic effect.
[0309] In summary, the analgesic effect of the glaucoma alkaloids provided by the embodiments of the present invention is better than that of ibuprofen to a certain extent. Although the water-washed part of the glaucoma alkaloids provided in Example 1 can reduce the number of paw licking of mice, the paw licking time is not reduced. After analyzing the data one by one, it was found that this was caused by the long single paw licking time of the mice in this group. Moreover, the water-washed part of the glaucoma alkaloids provided in Example 1 does not have an analgesic effect on paw pain, which indicates that the water-washed part of the glaucoma alkaloids provided in Example 1 does not have an analgesic effect on formalin-induced acute pain and inflammatory pain. 2.4.2 ELISA method to detect mouse serum IL-1β and PGE2 levels ( n=8):
[0310] The test results of serum IL-1β and PGE2 levels of mice in each group are summarized in the following table:
[0311]
[0312]
[0313] (Note: Compared with the blank control group, ###P<0.05; compared with the model control group, *P<0.05, **P<0.01, ***P<0.001)
[0314] It can be seen from the above table that the water-washed fraction of the glaucoma alkaloids provided in Example 1, the alcohol-washed fraction of the glaucoma alkaloids provided in Example 1, and the glaucoma alkaloids provided in each example group can all reduce inflammatory mediators to a certain extent, among which the glaucoma alkaloids provided in Example 1 have the strongest inhibitory effect (P<0.001), which is similar to the anti-inflammatory effect of the positive drug ibuprofen, indicating that the effective fraction of glaucoma may exert a certain analgesic effect by inhibiting inflammatory factors in serum.
[0315] 2.4.3 Western Blot Detection of TRPV1 Levels in Mouse Dorsal Root Ganglia (DGR)
[0316] Western Blot was used to detect the TRPV1 level in the isolated mouse dorsal root ganglia. Figure 2 As shown. Figure 2It can be seen that compared with the model group, the spatholobi alkaloids provided in Example 1 have the strongest effect on the expression level of TRPV1. Although the spatholobi alkaloids water-washed fraction and the spatholobi alkaloids alcohol-washed fraction provided in Example 1 also have an effect on the expression level of TRPV1, they are far less than the spatholobi alkaloids. The increase in TRPV1 level may be related to the warm nature of spatholobi.
[0317] 3. Conclusion
[0318] Based on the above results, the glaucoma amide alkaloids provided in each example (especially Example 1) may exert a significant analgesic effect by acting on the TRPV1 pathway and inhibiting serum inflammatory factors.
[0319] 1. Experimental Materials
[0320] 1.1 Drugs and reagents
[0321] Freeze-dried powder of the effective part of Heather strychnifolia, positive drug ibuprofen tablets (batch number 2212627, Shandong Xinhua Pharmaceutical Co., Ltd.), positive drug acetaminophen and tramadol tablets, pellitoryline reference substance (≥98%), fennel amide (≥98%) and pipersintenamide (≥95%).
[0322] 1.2 Instruments
[0323] KH-30E ultrasonic cleaner (Kunshan Hechuang Ultrasonic Instrument Co., Ltd.), YWLG-10A vacuum freeze dryer (Nanjing Yanwo Biotechnology Co., Ltd.), TGL16M refrigerated centrifuge (Shanghai Luxiangyi Centrifuge Instrument Co., Ltd.).
[0324] 1.3 Animals
[0325] SPF grade ICR mice, half male and half female, weighing (20±2) g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.
[0326] 2. Methods and Results
[0327] 2.1 Grouping
[0328] The subjects were randomly divided into groups (n=8). The specific grouping method is as follows.
[0329] Model group: The mice were intragastrically administered with 0.5% sodium carboxymethyl cellulose in physiological saline solution.
[0330] Ibuprofen group: ibuprofen solution (15 mg ibuprofen per kg mouse body weight per day) was administered intragastrically.
[0331] The tramadol-acetaminophen group was intragastrically administered with tramadol-acetaminophen solution (55 mg tramadol-acetaminophen per kg of mouse body weight per day).
[0332] Example 1 Low-dose group: intragastrically administered with the glaucoma alkaloids prepared in Example 1 (9 mg glaucoma alkaloids per kg mouse body weight per day).
[0333] Example 1 High-dose group: intragastrically administered with the glaucoma alkaloids prepared in Example 1 (36 mg glaucoma alkaloids per kg mouse body weight per day).
[0334] The low-dose group of Comparative Example 10 was intragastrically administered with the glaucoma alkaloids prepared in Comparative Example 10 (9 mg glaucoma alkaloids per kg of mouse body weight per day).
[0335] The high-dose group of Comparative Example 10 was intragastrically administered with the glaucoma alkaloids prepared in Comparative Example 10 (36 mg glaucoma alkaloids per kg of mouse body weight per day).
[0336] The pellitoryline group was intragastrically administered with pellitoryline (5 mg pellitoryline per kg of mouse body weight per day).
[0337] The fentanyl group was intragastrically administered with fentanyl (5 mg fentanyl per kg of mouse body weight per day).
[0338] Pipersintenamide group: Pipersintenamide was administered intragastrically (5 mg of Pipersintenamide per kg of mouse body weight per day).
[0339] The basic solution used for oral administration of the above-mentioned drug-administered groups was a physiological saline solution containing 0.5% by mass of sodium carboxymethyl cellulose.
[0340] 2.2 Experimental methods
[0341] Hot water tail flick experiment:
[0342] Adjust the instrument and mice, turn on the power, and control the temperature of the water bath at 50±0.5. Immerse the tail of the mouse 3cm into the constant temperature water bath, measure the time from the tail of the mouse entering the water to the water, and measure it for 3 consecutive times, with an interval of no less than 15min each time, and take the average of the 3 times as the basic pain threshold of the mouse. Then each group was given medication for 3 consecutive days, and the medication was given by gavage once a day. On the fourth day, another medication was given as the last gavage. The pain threshold was measured by immersing the tail of the mouse 3cm in a constant temperature water bath 30, 45, and 60min after the last gavage; if there is still no reaction after 15s, take the mouse out to avoid scalding, and its pain threshold is calculated as 15s, which is recorded as the pain threshold after medication. Using the measured basic pain threshold and pain threshold after medication, the pain threshold increase rate is calculated according to the following formula.
[0343] Pain threshold increase rate = (pain threshold after drug administration - pain threshold before drug administration) / basic pain threshold × 100%
[0344] Formalin-induced biphasic pain experiment in mice:
[0345] Three days before modeling, a fixed time was selected and the mice were gripped according to the gripping method during plantar injection to adapt them to the posture for injection. Each group was given the drug continuously for seven days, with oral administration once a day. On the 7th day, the mice were fasted but not watered for 6 hours before the last administration. 30 minutes after the last administration, the blank group was not treated, and the mice in the other groups were injected with 5% formalin solution (prepared with 0.9% saline solution) 1μl / g at the plantar of the left foot, with 8 mice in each group. After the injection, the mice were placed in an observation cage to observe the behavior of the mice in the acute pain period within 5 minutes and the inflammatory pain period within 20 to 60 minutes, and the specific standards are shown in the following table:
[0346] Rating Evaluation Criteria Level A Keep both feet on the ground and distribute your weight evenly Class B The injected foot lands gently C-Class Injection foot lift D-Class Licking and biting injection foot
[0347] After the injection of formalin solution, observe and record the number of occurrences of the corresponding rated behaviors for 60 minutes. Among them, the 0-5 minutes is the acute pain period, called the phase; the 10-20 minutes is the interval period; the 2-60 minutes is the inflammatory pain period, called the phase. Calculate the number of occurrences of different levels of behavior in phase I and phase II respectively. Calculate the pain score according to the following formula:
[0348] Pain score = 1×B+2×C+3×D
[0349] Among them, B is the number of times B-level evaluation grade behavior occurs; C is the number of times C-level evaluation grade behavior occurs; D is the number of times D-level evaluation grade behavior occurs.
[0350] Data processing: Graphpad Prism 9.0 software was used for data processing. One-way analysis of variance was used for comparison among multiple groups, and P < 0.05 indicated that the difference was statistically significant.
[0351] 2.3 Experimental Results
[0352] 2.3.1 Hot water tail flick test results
[0353] The results of the hot water tail flick experiment are summarized in the following table ( n=8):
[0354]
[0355] (Note: Compared with the model group, *P<0.05, **P<0.01, ***P<0.001.)
[0356] As can be seen from the above table, the glaucoma amide alkaloids provided in Example 1 have a higher effect on improving the pain threshold of mice than the glaucoma amide alkaloids provided in Comparative Example 10 at the same dose. After 30 minutes of administration, the glaucoma amide alkaloids provided in Example 1 can significantly increase the pain threshold of mice (P<0.01), and the effect is slightly stronger than that of ibuprofen and tramadol in the positive drug control group; after 45 minutes of administration, tramadol has the most significant improvement on the pain threshold of mice (P<0.001), and the glaucoma amide alkaloids provided in Example 1 have a similar effect on the improvement of the pain threshold of mice as tramadol; after 60 minutes of administration, the glaucoma amide alkaloids provided in Example 1 can significantly increase the pain threshold of mice (P<0.01).
[0357] 2.4.2 Experimental results of comprehensive pain scores of formalin biphasic pain mice
[0358] The results of the formalin-induced biphasic pain test in mice are summarized in the following table ( n=8):
[0359]
[0360]
[0361] (Note: Compared with the model group, *P<0.05, **P<0.01, ***P<0.001; compared with the acetaminophen and tramadol group, #P<0.05.)
[0362] As can be seen from the above table, the analgesic effect of the glaucoma alkaloids provided in Example 1 is stronger than that of the glaucoma alkaloids provided in Comparative Example 10. Compared with the model group, the low-dose group of glaucoma alkaloids provided in the phase of tramadol and Example 1 has similar analgesic effect, and can reduce the number of pains at all levels in mice (P<0.01); compared with tramadol, the high-dose group of glaucoma alkaloids provided in Example 1 has a more significant analgesic effect (P<0.05); ibuprofen has no effect on the pain of the phase. Compared with the model group, ibuprofen had a very significant analgesic effect in phase II (P<0.001), and the low-dose group of glaucoma alkaloids and tramadol provided in Example 1 also had good analgesic effects, but were generally inferior to ibuprofen; the high-dose group of glaucoma alkaloids provided in Example 1 had a very significant analgesic effect, and the analgesic effect was similar to that of ibuprofen; in phase II, compared with tramadol, the low-dose group of glaucoma alkaloids provided in Example 1 had a more significant analgesic effect (P<0.05).
[0363] 3. Conclusion
[0364] The glaucoma amide alkaloids (lyophilized powder) prepared in Example 1 can effectively retain their analgesic activity, and are superior to the glaucoma amide alkaloids provided in Comparative Example 10 in terms of the content of active ingredients and analgesic effect. Ibuprofen is a commonly used antipyretic analgesic, while acetaminophen and tramadol are used for cancer pain or chronic pain, and the glaucoma amide alkaloids prepared in Example 1 have an analgesic effect similar to or even better than the two, and can bring better analgesic effect to patients with pain. And relative to the three active ingredients in glaucoma amide alkaloids (pellitol, wind vine amide, pipersintenamide), the glaucoma amide alkaloids (lyophilized powder) prepared in Example 1 can jointly exert a better analgesic effect.
[0365] Embodiment 20
[0366] The celastric amide alkaloids obtained in Example 1 are purified to obtain analgesic drugs with different components. The preparation method is as follows:
[0367] Take an appropriate amount of the glaucoma alkaloids prepared in Example 1 and completely dissolve it in methanol to obtain a methanol solution. Mix the obtained methanol solution with alumina in a weight ratio of glaucoma alkaloids (lyophilized powder) to alumina of 1:1, and place it in a spinner flask. Concentrate under reduced pressure at 40-60°C to a dry powder state. Wet column loading and dry loading (the loading material is the glaucoma alkaloids prepared in Example 1). Perform gradient elution with petroleum ether-ethyl acetate. Gradient elution procedure: petroleum ether, petroleum ether-ethyl acetate mixed solution (volume ratio 95:5→90:10→85:15→80:20→75:25→70:30→65:35→60:40→55:45→50:50→45:55→40:60→35:65→30:70→25:75→20:80→15:85→10:90→5:95), ethyl acetate. The amount of solution used for each gradient elution was 5 BV.
[0368] The elution portions of petroleum ether:ethyl acetate = 90:10 (denoted as solution 1) and petroleum ether:ethyl acetate = 85:15 (denoted as solution 2) were respectively taken for chromatographic separation.
[0369] The methanol reconstitution solution of solution 1 was centrifuged at 10000rpm for 10 minutes, the supernatant was taken, passed through a 0.22μm microporous membrane, and applied to a preparative liquid phase. A Hanbang ODS preparative chromatographic column was used, and acetonitrile: water (87:13) was used for isocratic elution. The detection wavelength was 260nm and the flow rate was 3.5mL / min. The fractions where the wallwort was located and other fractions 1 were collected. The methanol reconstitution solution of solution 2 was centrifuged at 10000rpm for 10 minutes, the supernatant was taken, passed through a 0.22μm microporous membrane, and applied to a preparative liquid phase. A Hanbang ODS preparative chromatographic column was used, and acetonitrile: water (75:25) was used for isocratic elution. The detection wavelength was 260nm and the flow rate was 3.5mL / min. The fractions where the wind vine amide was located, the fractions where the pipersintenamide was located, and other fractions 2 were collected. Other fractions 1 and other fractions 2 were mixed to obtain other fractions.
[0370] The fractions containing pellitorine, the fractions containing fusinamide, the fractions containing pipersintenamide and other fractions were freeze-dried respectively to obtain analgesic drug 1, analgesic drug 2, analgesic drug 3 and analgesic drug 4 respectively.
[0371] Drug efficacy example 3: pain relief experiment in a mouse model of bone cancer pain
[0372] 1. Experimental Materials
[0373] 1.1 Drugs and reagents
[0374] Heather vine, positive drug ibuprofen tablets (batch number 2212627, Shandong Xinhua Pharmaceutical Co., Ltd.), positive drug acetaminophen and tramadol tablets, pellitoryline, fennel amide and pipersintenamide.
[0375] 1.2 Instruments
[0376] KH-30E ultrasonic cleaner (Kunshan Hechuang Ultrasonic Instrument Co., Ltd.), YWLG-10A vacuum freeze dryer (Nanjing Yanwo Biotechnology Co., Ltd.), TGL16M refrigerated centrifuge (Shanghai Luxiangyi Centrifuge Instrument Co., Ltd.).
[0377] 1.3 Animals
[0378] SPF grade ICR mice, half male and half female, weighing (20±2) g, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.
[0379] 2. Methods and Results
[0380] 2.1 Grouping
[0381] Random grouping (n=8), the specific grouping scheme is as follows:
[0382] Bone cancer pain group: An animal model of bone cancer pain was established (see the "Experimental Methods" section for the specific process), and a physiological saline solution containing 0.5% sodium carboxymethyl cellulose was administered by intragastric administration.
[0383] Sham operation group: The difference from the bone cancer pain group is that the in situ injection of tumor cells was replaced by the in situ injection of an equal volume of normal saline, and the rest was the same.
[0384] Bone cancer pain + ibuprofen group: An animal model of bone cancer pain was established, and ibuprofen was administered by oral gavage (daily dose of 30 mg / kg mouse body weight).
[0385] Bone cancer pain + tramadol acetaminophen group: A bone cancer pain animal model was established, and tramadol acetaminophen was administered by gavage (daily dose of 30 mg / kg mouse body weight).
[0386] Example 1 Group: An animal model of bone cancer pain was established, and the celastrin amide alkaloids provided in Example 1 were administered orally (daily dose was 30 mg / kg mouse body weight).
[0387] Example 1 + analgesic drug 1-3 group: An animal model of bone cancer pain was established, and the glaucoma amide alkaloids provided in Example 1 and analgesics 1, 2 and 3 provided in Example 20 were administered by gavage (the total daily dose was 30 mg / kg mouse body weight, and the mass ratio of the glaucoma amide alkaloids provided in Example 1 and analgesics 1, 2 and 3 provided in Example 20 was 100:3:3.6:14).
[0388] Analgesic drug groups 1-3: An animal model of bone cancer pain was established, and analgesic drugs 1, 2 and 3 provided in Example 20 were administered orally (the total daily dose was 30 mg / kg mouse body weight, and the mass ratio of analgesic drugs 1, 2 and 3 provided in Example 20 was 3:3.6:14).
[0389] Analgesic drug group 4: A bone cancer pain animal model was established, and analgesic drug 4 provided in Example 20 was administered by oral gavage (daily dose of 30 mg / kg mouse body weight).
[0390] The basic solution used in the above-mentioned oral administration groups was a physiological saline solution containing 0.5% by mass of sodium carboxymethyl cellulose.
[0391] 2.2 Experimental methods
[0392] Bone cancer model: Use an intelligent hot plate as the heat source, adjust the temperature to 55±0.5, and screen mice with a pain threshold within 5-30s.
[0393] The method for measuring the pain threshold of mice by the hot plate method is as follows:
[0394] Mice with bone cancer model were randomly divided into groups and placed on a constant temperature hot plate. The pain threshold was measured three times with an interval of no less than 15 minutes each time. The time from when the mouse was placed on the hot plate to when it jumped up or licked its feet was recorded, and the average of the three times was taken as the basic pain threshold of the mouse. The drug was administered continuously for 7 days, with oral administration once a day. After the last administration, the mice were placed on a constant temperature hot plate at 30, 45, and 60 minutes to measure their pain threshold; if there was still no reaction after 60 seconds, the mouse was taken out to avoid burns, and its pain threshold was calculated based on 60 seconds.
[0395] The selected mice were anesthetized and placed in a supine position. The left hind limb was clipped and disinfected. A 0.5-1.0 cm long skin incision was made along the rectus femoris tendon at the knee joint to carefully expose the patella. A disposable sterile 1 mL syringe needle was used to puncture the patella along the long axis of the femur. Then a 10 μL syringe was used to enter the femoral medullary cavity. 10 μL of Lewis cells (3×10 5 After the injection, the mice were sutured and disinfected, and then put back into the cage after they woke up.
[0396] The sham operation group was injected with 0.9% saline solution, and the rest of the treatment was the same as above.
[0397] Pain threshold increase rate = (pain threshold after administration - basic pain threshold) / basic pain threshold × 100%
[0398] Data processing: Graphpad Prism 9.0 software was used for data processing. One-way analysis of variance was used for comparison among multiple groups, and P < 0.05 indicated that the difference was statistically significant.
[0399] 2.3 Experimental Results
[0400] The results of the pain threshold increase rate of bone cancer pain model mice are summarized in the following table ( n=8):
[0401]
[0402]
[0403] (Note: Compared with group M, *P<0.05, **P<0.01, ***P<0.001)
[0404] The results showed that compared with the sham operation group, the mice induced by bone cancer had pain hypersensitivity and a lower basal pain threshold. In the absence of drug interference, the pain threshold did not change significantly, indicating that this model can evaluate the effects of drugs on cancer pain. As can be seen from the above table, ibuprofen has almost no analgesic effect on bone cancer-induced pain hypersensitivity, which shows that non-opioid drugs cannot effectively relieve pain in mice induced by bone cancer. Weak opioids can significantly increase the pain threshold of mice and have a significant analgesic effect (P<0.01). After knocking out the three components of linalool, fennel amide and pipersintenamide, the analgesic effect of linalool amide alkaloids was reduced, but it had an effect of improving the pain threshold of bone cancer mice (P<0.05). When the three active ingredients were added to linalool amide alkaloids, the analgesic effect was significantly improved (P<0.001), and when the three active ingredients were used alone, they also had a certain analgesic effect (P<0.01), indicating that linalool amide alkaloids mainly exert significant analgesic effects through the combined action of these three active ingredients and other amide alkaloids with relatively low contents.
[0405] 3. Conclusion
[0406] Pipersintenamide alkaloids have a significant analgesic effect on cancer pain, exerting their effects through pelargonine, pipersintenamide, pipersintenamide and other amide alkaloids. The analgesic effect is fast-acting, strong, and has an outstanding sustained analgesic effect, and has significant value.
[0407] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A celastron amide alkaloid, characterized in that: The mass content of total alkaloids in the celastrin alkaloids is 50.03%-55.58%, the mass content of celastrin alkaloids is 22.28‰-31.10‰, and the mass content of pellitoryline is 9.18%-13.95%; The UPLC fingerprint of the celastron amide alkaloids includes fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11, the position of the fingerprint peak 1 is 3.90-4.10min, the position of the fingerprint peak 6 is 12.45-12.55min, the position of the fingerprint peak 7 is 12.80-12.95min, the position of the fingerprint peak 9 is 13.10-13.25min, and the position of the fingerprint peak 11 is 15.30-15.45min.
2. The celastrin amide alkaloid according to claim 1, characterized in that The chromatographic conditions of the UPLC include: Chromatographic column: C 18 Chromatographic columns; With water as mobile phase A and acetonitrile as mobile phase B, the gradient elution scheme is as follows: The column temperature was 35°C, the flow rate was 0.8 mL / min, and the detection wavelength was 260 nm.
3. The celastrin amide alkaloid according to claim 1, characterized in that The UPLC fingerprint of the celastron amide alkaloids also includes fingerprint peak 2, fingerprint peak 3, fingerprint peak 4, fingerprint peak 5, fingerprint peak 8 and fingerprint peak 10, the position of the fingerprint peak 2 is 5.85-6.05min, the position of the fingerprint peak 3 is 8.85-8.95min, the position of the fingerprint peak 4 is 9.30-9.50min, the position of the fingerprint peak 5 is 12.15-12.30min, the position of the fingerprint peak 8 is 13.00-13.05min, and the position of the fingerprint peak 10 is 13.90-14.00min.
4. The celastrin amide alkaloid according to claim 1, characterized in that The component corresponding to the fingerprint peak 1 is Ziyupandiamide; The component corresponding to the fingerprint peak 6 is fusinamide; The component corresponding to the fingerprint peak 7 is Pipersintenamide; The component corresponding to the fingerprint peak 9 is pellitoryline; The component corresponding to the fingerprint peak 11 is (2E, 4E)-N-(2-methylpropyl)-dodeca-2,4-dienamide.
5. The celastrin amide alkaloid according to claim 1, characterized in that The ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.435-1.868: 1.053-1.470: 1.505-1.986: 10.950-16.640: 0.975-1.
040.
6. The method for preparing the celastrin amide alkaloids according to any one of claims 1 to 5, characterized in that: The following steps are involved: S1, mixing the heather vine with an ethanol aqueous solution, and performing reflux extraction to obtain an extract; S2, mixing the extract obtained in step S1 with a macroporous adsorption resin, stirring, and concentrating under reduced pressure until there is no alcohol taste, to obtain a sample mixture; S3, loading the loading mixture obtained in step S2, letting it stand, flowing out, eluting, and obtaining an eluate; S4, concentrating the eluate obtained in step S3 under reduced pressure, and drying to obtain celandine amide alkaloids.
7. The preparation method according to claim 6, characterized in that: In step S1, the concentration of the ethanol aqueous solution is 70%-80%, and the mass ratio of the heather spatholobi to the ethanol aqueous solution is 1:10-20; the reflux extraction is performed 1-3 times, and each extraction takes 1-4 hours.
8. The preparation method according to claim 6, characterized in that: In step S2, the type of the macroporous resin is selected from HP-20, D101, S-8, NKA-9, DA201 and HP2MGL.
9. The preparation method according to claim 6, characterized in that: The ratio of the weight of the heather vine in step S1 to the dry weight of the macroporous resin in step S2 is 1:0.4-1.2; in step S2, the reduced pressure concentration is carried out at 40-60°C.
10. The preparation method according to claim 6, characterized in that: In step S3, the standing still is 15-30 minutes, and the outflow rate is 2-4 BV / h.
11. The preparation method according to claim 6, characterized in that: In step S3, the elution comprises the following steps: S31, 3-5 BV of water is eluted at a flow rate of 2-4 BV / h to obtain a water-washed part liquid; S32, eluting 3-5 BV with a 25%-30% ethanol aqueous solution at a flow rate of 2-4 BV / h to obtain an alcohol wash fraction solution; S33. Elute 9-12 BV with 70%-80% ethanol aqueous solution at a flow rate of 2-4 BV / h to obtain an eluate.
12. The preparation method according to claim 6, characterized in that: In step S4, the reduced pressure concentration is performed at 40-60° C., and the drying is freeze-drying.
13. A water-washed fraction of celastron amide alkaloids, characterized in that: The preparation method of the water-washed part of the celastron amide alkaloids comprises the following steps: In the preparation method according to claim 11, the water-washed fraction liquid obtained in step S31 is dried to obtain the celastron amide alkaloid water-washed fraction.
14. An alcohol-washed fraction of celastrin amide alkaloids, characterized in that: The preparation method of the alcohol-washed part of the celastron amide alkaloids comprises the following steps: In the preparation method according to claim 11, the alcohol washing fraction obtained in step S32 is dried to obtain the alcohol washing fraction of the celastron amide alkaloids.
15. Use of the briar amide alkaloids described in any one of claims 1 to 5, or the briar amide alkaloids obtained by the preparation method described in any one of claims 6 to 12, or the water-washed fraction of the briar amide alkaloids described in claim 13, or the alcohol-washed fraction of the briar amide alkaloids described in claim 14 in the preparation of analgesic products.
16. An analgesic drug, characterized in that: The active ingredients include the briar amide alkaloids described in any one of claims 1-5, or the briar amide alkaloids obtained by the preparation method described in any one of claims 6-12, or the water-washed part of the briar amide alkaloids described in claim 13, or the alcohol-washed part of the briar amide alkaloids described in claim 14.
17. A quality standard for celastrin alkaloids, characterized in that: Including total alkaloid content detection, fusinamide content detection, pellitoryline content detection and UPLC fingerprint detection of fusinamide alkaloids; The UPLC fingerprint detection method of the celastrin alkaloids comprises the following steps: The sedum amide alkaloids were dissolved in 75% methanol, sonicated to remove solids, injected into a liquid chromatograph for UPLC detection, and a UPLC fingerprint was obtained; The quality of celastrin amide alkaloids was evaluated based on the obtained UPLC fingerprints, and the evaluation criteria included: (1) The UPLC fingerprint spectrum includes fingerprint peak 1, fingerprint peak 6, fingerprint peak 7, fingerprint peak 9 and fingerprint peak 11, the position of the fingerprint peak 1 is 3.90-4.10 min, the position of the fingerprint peak 6 is 12.45-12.55 min, the position of the fingerprint peak 7 is 12.80-12.95 min, the position of the fingerprint peak 9 is 13.10-13.25 min, and the position of the fingerprint peak 11 is 15.30-15.45 min; (2) The UPLC fingerprint spectrum also includes fingerprint peak 2, fingerprint peak 3, fingerprint peak 4, fingerprint peak 5, fingerprint peak 8 and fingerprint peak 10. The position of the fingerprint peak 2 is 5.85-6.05 min, the position of the fingerprint peak 3 is 8.85-8.95 min, the position of the fingerprint peak 4 is 9.30-9.50 min, the position of the fingerprint peak 5 is 12.15-12.30 min, the position of the fingerprint peak 8 is 13.00-13.05 min, and the position of the fingerprint peak 10 is 13.90-14.00 min.
18. The quality standard according to claim 17, characterized in that The standard for the total alkaloid content detection is: total alkaloid mass content ≥ 50.05%; The standard for the detection of the content of fennel amide is: the mass content of fennel amide is ≥ 22.28‰; The standard for detecting the content of pellitoryline is: the mass content of pellitoryline is ≥ 9.18%.
19. The quality standard according to claim 17, characterized in that The chromatographic conditions of the UPLC detection include: Chromatographic column: C 18 Chromatographic columns; With water as mobile phase A and acetonitrile as mobile phase B, the gradient elution scheme is as follows: The column temperature was 35°C, the flow rate was 0.8 mL / min, and the detection wavelength was 260 nm.
20. The quality standard according to claim 17, characterized in that The ratio of the peak areas of the fingerprint peak 1, the fingerprint peak 6, the fingerprint peak 7, the fingerprint peak 9 and the fingerprint peak 11 is 1.435-1.868: 1.053-1.470: 1.505-1.986: 10.950-16.640: 0.975-1.040.
Citation Information
Patent Citations
Liquid phase analysis method for simultaneously detecting 12 amide alkaloids in Piper laetispicum
CN103063789A
A preparing method for a tylophora ovate alkaloid extract product and a detecting method therefor
CN106166167A
Quality detection method of eucommia ulmoides bone strengthening pills
CN110320311A
Application of pellicine in quality detection of kadsura pepper stem sample and corresponding quality detection method
CN116559302A
Enrichment and purification method of total lignans in piper wallichii and application of enrichment and purification method
CN117982561A
Cited By
Characteristic chromatogram construction method of piper wallichii medicinal material or preparation thereof
CN120992799A
